Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Glioblastoma 203Brain Neoplasms 94Gliosarcoma 93Glioma 88Central Nervous System Neoplasms 78Astrocytoma 66Oligodendroglioma 45Melanoma 37Medulloblastoma 18Neuroblastoma 17Neoplasm Metastasis 14Ependymoma 13Neoplasms 10Choroid Plexus Neoplasms 10Sarcoma 9Recurrence 9Optic Nerve Glioma 9Familial ependymoma 9Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Lung Neoplasms 8Spinal Cord Neoplasms 7Breast Neoplasms 7Uveal Melanoma 6Sarcoma, Ewing 6Rhabdoid Tumor 6Pinealoma 6Neuroectodermal Tumors, Primitive 6Unspecified Adult Solid Tumor, Protocol Specific 5Small Cell Lung Carcinoma 5

Interventions

adavosertib 2veliparib 1trametinib 1pamiparib 1cabozantinib 1Temozolomide 1Everolimus 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignant Solid Neoplasm × Temozolomide × Clear all
NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

National Cancer Institute (NCI)

Phase 2 Completed
208 enrolled 27 charts
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡